Overview

First-in-Human Study of EOS100850 in Patients With Cancer

Status:
Recruiting
Trial end date:
2022-12-31
Target enrollment:
0
Participant gender:
All
Summary
Multicenter, open-label, dose-escalation Phase I/Ib clinical study to evaluate the safety and tolerability, the MTD/RP2D, pharmacokinetics (PK), pharmacodynamics (PD), and antitumor activity of EOS100850 as a Single Agent and in Combination with Pembrolizumab and/or Chemotherapy in Participants with Advanced Cancers.
Phase:
Phase 1
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
iTeos Therapeutics
Collaborator:
Merck Sharp & Dohme Corp.
Treatments:
Pembrolizumab
Criteria
For more information regarding participation in the Trial, please refer to your physician

Inclusion Criteria:

- Women and men ≥18 years of age with Eastern Cooperative Oncology Group (ECOG)
performance status of 0 or 1

- Subject with histologically or cytologically confirmed advanced solid tumor for whom
no standard treatment is further available.

- At least 4 weeks since any previous treatment for cancer

- Subject must consent to pretreatment and on treatment tumor biopsies

- Adequate organ and marrow function

Exclusion Criteria:

- Patients with primary brain tumors or primary tumors with central nervous system
metastases as only location of disease. Controlled brain metastases are permitted

- Participants with second/other active cancers requiring current treatment

- Uncontrolled/significant heart disease

- Known History of chronic hepatitis, Positive test for Hepatitis B virus surface
antigen or Hepatitis C antibody (except participants with liver cancer) or Human
Immunodeficiency Virus/Acquired Immunodeficiency Syndrome(HIV/AIDS)

- Active/uncontrolled autoimmune disease

- Active infection

Other protocol defined inclusion/exclusion criteria could apply